Abstract: Clear cell papillary renal cell carcinoma (ccpRCC) and renal angiomyoadenomatous tumor (RAT) share morphologic similarities with clear cell (ccRCC) and papillary RCC (pRCC). It is a matter of controversy whether their morphologic, immunophenotypic, and molecular features allow the definition of a separate renal carcinoma entity. The aim of our project was to investigate specific renal immunohistochemical biomarkers involved in the hypoxia-inducible factor pathway and mutations in the VHL gene to clarify the relationship between ccpRCC and RAT. We investigated 28 ccpRCC and 9 RAT samples by immunohistochemistry using 25 markers. VHL gene mutations and allele losses were investigated by Sanger sequencing and fluorescence in situ hybridization. Clinical follow-up data were obtained for a subset of the patients. No tumor recurrence or tumor-related death was observed in any of the patients. Immunohistochemistry and molecular analyses led to the reclassification of 3 tumors as ccRCC and TFE3 translocation carcinomas. The immunohistochemical profile of ccpRCC and RAT samples was very similar but not identical, differing from both ccRCC and pRCC. Especially, the parafibromin and hKIM-1 expression exhibited differences in ccpRCC/RAT compared with ccRCC and pRCC. Genetic analysis revealed VHL mutations in 2/27 (7%) and 1/7 (14%) ccpRCC and RAT samples, respectively. Fluorescence in situ hybridization analysis disclosed a 3p loss in 2/20 (10%) ccpRCC samples. ccpRCC and RAT have a specific morphologic and immunohistochemical profile, but they share similarities with the more aggressive renal tumors. On the basis of our results, we regard ccpRCC/RAT as a distinct entity of RCCs.
C lear cell papillary renal cell carcinoma (ccpRCC) has been proposed as a new entity of renal cell cancer by the International Society of Urological Pathology to be included in the next World Health Organization Classification of Renal Tumors. 1 It was initially discovered in kidneys with end-stage renal disease in 2006. 2 Since then >100 ccpRCC cases have been described, and the majority were found in normal functioning kidneys. [3] [4] [5] [6] [7] [8] They are characterized by tumor cells with clear cytoplasm, linear arrangement of low-grade nuclei located apically distant from the basal membrane, and containing varying amounts of tubular, papillary, and cystic architecture. Strikingly, the ccpRCCs lack mitoses, atypia, pleomorphism, necrosis, hyaline globules, foamy macrophages, and vascular invasion. Despite significant morphologic, immunohistochemical, and genetic similarities to clear cell RCC (ccRCC) and papillary RCC (pRCC), characteristic genetic differences include VHL gene mutations and 3p losses, found in ccRCC. Gain of the chromosomes 7 and 17 or loss of chromosome Y are absent or extremely rare in ccpRCC cases. 4, 9, 10 No disease-defining mutation has been identified to date.
The renal angiomyoadenomatous tumor (RAT) was first reported in the kidney of a 93-year-old man by Michal et al. 11 Nine years later, the same group characterized 5 additional tumors. 12 Verine 13 pointed out that ccpRCCs are a major differential diagnosis of RAT and emphasized their morphologic, immunohistochemical, molecular, and clinical similarities. In the literature many terms have been used to probably describe the same entity, including ccRCC with prominent leiomyomatous proliferation and RCC with smooth muscle stroma. 12, [14] [15] [16] [17] The epithelial component of ccpRCC and RAT is composed of cells with abundant clear cytoplasm, strong diffuse CK7 activity, and low-grade nuclei (Fuhrman grades 1 and 2). Because of their many similarities, several authors regard ccpRCC and RAT to be a variant of the same entity. 6, 9, 13, 17, 18 The aims of our study were to clarify the relationship between ccpRCC and RAT and to identify markers to reliably distinguish ccpRCC and RAT from the biologically more aggressive renal neoplasms.
MATERIALS AND METHODS

Case Cohort
All tumors were consultation cases from H.M. and E.C. and were received from Austria, France, Germany, Italy, and Switzerland. Hematoxylin and eosin-stained slides were reviewed for morphologic features of ccpRCC and RAT as previously described. 3, [5] [6] [7] 11, 12, 19 Diagnostic features of ccpRCC include tumor cells with abundant clear cytoplasm, varying papillary, cystic, and tubular architecture, low-grade nuclei (Fuhrman grades 1 and 2) located apically distant from the basal membrane, and strong diffuse CK7 and CA-IX expression. For diagnosis of RAT, the following criteria were required: cells with clear cytoplasm, low-grade nuclei (Fuhrman grades 1 and 2) embedded in a smooth muscle stroma, and strong diffuse CK7 staining of the epithelial component. Tumors were staged according to the TNM system 20 and graded according to Fuhrman et al. 21 The morphologic characteristics were scored as previously described. 7 
Immunohistochemistry
A total of 25 antibodies were selected as (i) they are involved in the VHL signaling pathway, (ii) they are known to be prognostic biomarkers of ccRCC, and (iii) they have been reported as markers of ccpRCCs and RATs in a small group of ccpRCCs described in recent USCAP meetings (2011 to 2014). Tissue microarray sections (2.5 mm) were transferred to glass slides and treated using Ventana Benchmark XT, Bondmax (Leica Microsystems) automated systems, and manual protocols. Tissue microarray construction was not possible in 5 of the ccpRCC cases because of the absence of tissue. The immunohistochemical staining product was described as nuclear, membranous, or cytoplasmic (Table 1) . The immunohistochemistry results were interpreted as 0 (negative), 1+ (weak staining), 2+ (moderate staining), and 3+ (strong staining). For statistical analysis, all 2+ and 3+ stainings were defined as positive and 0 and 1+ as negative. Antibodies and protocols are listed in Table 1 .
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH), performed to detect VHL allele losses, was carried out using the ZytoLight SPEC VHL/CEN 3 Dual-color Probe (ZytoVision, Bremerhaven, Germany). Tissue sections were cut from formalin-fixed paraffin-embedded (FFPE) blocks, deparaffinized, and hybridized as previously described. 22 Sixty nonoverlapping tumor nuclei from 3 different areas were analyzed, and the number of VHL and CEN3 signals was recorded for each nucleus. The total number of VHL and CEN3 signals as well as the VHL/CEN3 ratio and the percentage of tumor cells with <2 VHL signals were calculated. Tumors were considered VHL deleted if >50% of the tumor nuclei displayed <2 VHL signals. 23 In 2 cases TFE3 FISH using SPEC TFE3 dual-color break-apart probe from ZytoVision was performed on whole sections as previously described by our group. 24 
VHL Sequencing Analysis
Tumor areas displaying >80% tissue in the epithelial portion of the ccpRCC and RAT were marked on the hematoxylin and eosin slides. DNA from FFPE tumor tissue samples was obtained by punching 1 to 2 tissue cylinders (diameter 0.6 mm) from each sample. DNA was extracted from the tumor tissue samples according to the Maxwell 16 FFPE Plus DNA Purification protocol (Promega, Fitchburg) for automated DNA purification. DNA concentrations in the samples were measured using the Nanodrop (Thermo Fisher Scientific, Waltham, MA). Polymerase chain reaction (PCR) of the VHL gene was performed as previously described 25 using approximately 40 ng of DNA for each amplification. DNA sequencing was performed with the dideoxy chain-termination method using the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Foster City). The same forward and reverse primers were used for PCR and sequencing analyses. Cycle sequencing products were analyzed using the AbiPrism 3100 Genetic analyzer (Applied Biosystems). The obtained sequences were compared with the NCBI sequence AF010238 using NCBIs Blast 2 Sequences. All VHL point mutations obtained were validated by a second separate PCR and sequencing analysis.
RESULTS
Clinical and Pathologic Findings
The patients with ccpRCC ranged from 29 to 75 years of age (mean age 58 y) and those with RAT from 32 to 68 years of age (mean age 43.3 y) at the time of nephrectomy. The male to female ratio was 1.5:1 in the ccpRCC group (17 men and 11 women) and 3.5:1 in the RAT group (6 men and 1 woman).
Clinical follow-up data were available for 78% (21/ 27) of the ccpRCC patients and 71% (5/7) of the RAT patients. Mean follow-up time was 29.7 months (range, 7 to 84 mo) for the ccpRCC patients and 32.3 months (range, 25 to 38 mo) for the RAT patients. There was no evidence of recurrence or disease-related death in any of the patients. None of the RAT (0/5) patients and 14% (3/ 22) of the ccpRCC patients had end-stage renal disease.
In the RAT group, the average diameter of the tumor was 3.1 cm (range, 1.8 to 5.0 cm) compared with 2.6 cm (range, 0.5 to 8 cm) in the ccpRCC group. Among the RAT patients, 67% (4/6) displayed pathologic stage pT1a and 33% (2/6) stage pT1b. Overall, 86% of the tumors (6/7) were Fuhrman nuclear grade 1, and 14% (1/7) were nuclear grade 2. In the ccpRCC cases, 77% (20/26) were stage pT1a, 19% (5/26) were pT1b, and 4% (1/26) were pT2a. Fuhrman nuclear grade 1 was found in 48% (13/27) and nuclear grade 2 in 52% (14/27) of the tumors. All the ccpRCCs and 6/7 RATs showed at least focal papillary architecture and branched ducts. In contrast to ccpRCC, secretory cells were completely absent in the RAT cases. Both showed variable amounts of cystic areas. All tumors were characterized by the absence of mitotic formations, foamy macrophages, calcifications, and vascular invasion. Table 2 summarizes the clinicopathologic findings. Morphologic characteristics are shown in Table 3 .
Immunohistochemical Findings
The immunohistochemical findings are detailed in Table 4 . ccpRCC and RAT were strongly positive for CK7, CK19, CA-IX, GLUT-1, E-cadherin, vimentin, b-catenin, parafibromin, PAX-2, PAX-8, p27, p53, and c-MET. Staining for GLUT-1 (P = 0.0572), CD70 (P = 0.1499), and p16 (P = 0.3702) differed slightly in the RAT samples compared with ccpRCCs, although differences did not show statistical significance. Following the recent results by Cui et al, 26 Aron et al, 27 and Schwartz et al, 28 we tested parafibromin, hKIM-1, 29 and CD133 expression to distinguish ccpRCC/RAT from ccRCC/pRCC. As shown in Table 5 , the expression difference reached statistical significance (P < 0.0001). The biomarkers CD70, 30 MET, 31 and E-cadherin 32 were able to distinguish between ccpRCC/RAT and ccRCC (P < 0.0001). Furthermore, the hKIM-1 and parafibromin were able to distinguish between ccpRCC/RAT and pRCC. All ccpRCC cases exhibited a characteristic CA-IX "cup-like" distribution, sparing the luminal border as it has been described in the literature before. 6, 33 In contrast, the RAT tumors and the ccpRCC-like tumor with the VHL mutation showed a circumferential membranous staining pattern. Two RAT samples stained weakly positive for TFE3 and were, therefore, further analyzed by HMB45 and TFEB. Both stainings revealed a negative result. In addition, TFE3 FISH was performed (see below).
FISH Findings
Three deletions of the short arm of chromosome 3 were identified. All of them occurred in the ccpRCC cases (3/21, 14%), and no deletion was found in the RAT cases (0/7, 0%). The presence of the 3p deletions in the 1 ccRCC controls was correctly identified. In 9 of the cases FISH was not performed, as there was insufficient tissue after VHL mutation analysis and immunohistochemistry.
TFE3 FISH was performed with the 2 above-mentioned RAT-like cases that showed weak TFE3 expression. One case showed the typical break-apart pattern 
VHL Gene Mutation Analysis
Three VHL mutations were detected in the ccpRCC group (3/27, 11%) in exon 2 (c.351G > C/p.Trp117Cys, c.461C > T/p.Pro154Leu, c.388G > C/p.Val130Leu) and 1 in the RAT group (1/7, 14%) in exon 1 (c.174_177delGCCG/ p.Pro59GlyfsX7). We identified 2 cases, harboring both a VHL mutation and 3p loss. One case showed a 3p loss but no VHL mutation, and 2 cases with a VHL mutation showed no 3p loss (Figs. 1-5) .
DISCUSSION
In the present study we have sequenced the largest number of ccpRCC 29 and RAT 7 cases to date. We found a VHL mutation rate of 11% in ccpRCC and 14% in RAT. Furthermore, we analyzed hypoxia-inducible factor pathway-related proteins to compare these findings with recent findings.
ccpRCC and RAT are currently underrecognized. Recent studies have revealed that they are not rare 7, 34, 35 and that among all RCCs the ccpRCCs have a prevalence rate between 1.2% and 4.1%, thus representing up to 4500 new cases of renal cancer in the United States annually. 7, 34, 36 Awareness of its morphologic and immunohistochemical features is imperative for a correct classification. In a recent publication Gill et al 35 underscored the necessity of reclassifying low-grade and low-stage ccRCC, as up to 7% of the cases are in fact ccpRCC.
Morphologically, ccpRCC and RAT share many features. Their epithelial component is composed of cells with clear cytoplasm and low-grade nuclei. Both tumors have various amounts of smooth muscle stroma, and their epithelial component is characterized by either cystic or papillary architecture. In our cohort the majority of the RAT samples had focal papillary features of the epithelial 38, 39 To rule out this differential diagnosis, we performed 2 additional immunohistochemical stainings (HMB45 and TFEB). Both stainings showed a negative result making that differential diagnosis unlikely.
One ccpRCC case was reclassified as ccRCC. That case exhibited typical ccpRCC morphology but was completely negative for CK7 and strongly positive for hKIM-1. This case also revealed a mutation in the VHL gene and a 3p loss in the FISH analysis. These findings highlight the importance of molecular testing and should raise awareness of ccpRCC mimicking ccRCC. 40 VHL gene mutations are the genetic hallmark of ccRCC. Initially, it was reported that VHL alterations are absent in ccpRCC. However, 3 groups have recently identified VHL mutations in ccpRCC at frequencies varying from 15% to 27%. [41] [42] [43] In concordance with these studies, we also identified VHL gene alterations in ccpRCC, but the prevalence of VHL gene mutations is significantly lower than in ccRCC. [44] [45] [46] The discrepancy between the number of mutations found in our ccpRCC cases and that reported may be explained by the different detection methods used, including single-nucleotide polymorphism genotyping array and Sanger sequencing, and by the limited number of cases in previous studies. Alternatively, cases with VHL mutations could represent ccRCCs with morphology and immunoprofile closely mimicking that of clear ccpRCC and RAT tumor. Currently, ccpRCCs are diagnosed on the basis of morphology and diffuse strong CK7 expression. The absence of VHL mutations/3p deletions is not diagnostic for ccpRCC. Therefore, we suggest diagnosis of tumors with diffuse CK7 expression combined with the typical morphology as ccpRCC. In previous studies, ccRCCs with a diffuse CK7 profile have had a completely different prognosis than ccRCCs without that CK expression pattern. 47 These previous findings justify such an approach.VHL inactivation leads to an HIF-dependent CA-IX and GLUT-1 upregulation. We only found few VHL mutations but in combination with CA-IX and GLUT-1 immunoreactivity in both ccpRCC and RAT. This clearly sets the ccpRCC and RAT apart from ccRCC, which shows VHL mutations in up to 80% of the cases. 44, 48 Therefore, we believe that the HIF pathway may be activated in a VHL-independent manner in most ccpRCCs and RATs, also hypothesized by Rohan et al. 6 Recently, Lawrie et al 49 found various mutations in ccpRCC by using next-generation sequencing, including a nonsynonymous T992I mutation in the MET proto-oncogene. This gene was originally described as causing hereditary pRCC. 50 Interestingly, Lawrie and colleagues detected no VHL mutation, but found overexpression in all 5 members of the miR-200 family. The miR-200 family plays an essential role in tumor suppression by inhibiting epithelial-mesenchymal transition. 51 To support Lawrie and colleagues' results, we also noted immunoreactivity for E-cadherin and b-catenin. These findings suggest that epithelial-to-mesenchymal transition may be incomplete or blocked in ccpRCC contributing to their indolent course. 49 Other genetic alterations characteristic for pRCC include gain of chromosome 7 and loss of chromosome Y. However, in ccpRCC, gain of chromosome 7 has very rarely been reported, 4, 5, 9, 10 and no loss of chromosome Y has been observed to date. Fisher et al 52 found a unique gene expression profile of ccpRCC when investigating 8 different genes, with only some expression levels comparable to those observed in ccRCC and pRCC.
In our FISH analysis, we identified 3 chromosome 3p deletions in 20 ccpRCC and 7 RAT samples. All 3p deletions occurred in ccpRCC with a frequency of 14.3%, but none was detected in RAT. To date, only 4 cases with a 3p loss have been reported in ccpRCC. 36, 43 Interestingly, the single case described by Martignoni et al 43 concurrently harbored a VHL mutation like 2 of our 3 cases with a 3p loss. Shi et al 36 also used FISH and observed monosomy of chromosome 3 in 3 cases in a series of 11 ccpRCCs all lacking mutations in the VHL gene. In 2009, Shannon et al 14 published a study on 5 ccRCCs with smooth muscle stroma and found loss of the entire chromosome 3 in 2 cases and a 3p loss in 1 case using FISH. In contrast, Martignoni et al 17 found no 3p loss in a series of 3 cases of ccRCC with smooth muscle stroma. Given these molecular findings, it has been suggested that RAT and ccRCC with smooth muscle stroma are interchangeable terms. 53 However, some of the cases of ccRCC with smooth muscle stroma, particularly those that showed 3p loss, might represent ccRCCs with exuberant, infiltrative smooth muscle, whereas the others might in fact be RAT tumors, particularly the ones that do not show 3p loss. 15 In addition, recent data show that some tumors with RAT morphology and immunophenotype share a common mutation in the TCEB1 gene, which inactivated the VHL pathway and upregulated proteins along the hypoxiainducible pathway. 54 Twenty-five different antibodies were used to characterize ccpRCC and RAT. We were particularly interested in hypoxia-inducible factor pathway-related proteins and other antibodies, which were reportedly used in small series of ccpRCC cases in the 2011 and 2014 USCAP meetings. This gave us the opportunity to compare immunohistochemical findings in ccpRCC and RAT to clarify their interrelationship. Remarkably, there were no statistically significant differences in the staining properties in any of the antibodies in ccpRCC compared with RAT.
Parafibromin and hKIM-1 expression levels differed significantly between ccpRCC/RAT and ccRCC/pRCC. Cui et al 26 recently demonstrated that parafibromin can be very helpful in differentiating ccpRCC from ccRCC and pRCC. In a study by Aron et al, 27 the difference in the staining positivity rate of ccpRCC and ccRCC was even more striking compared with our study. In addition to parafibromin and hKIM-1 expression, CD70 also proved to be a useful marker in differentiating ccpRCC from ccRCC, as CD70 expression is rare in ccpRCC and very frequent in ccRCC. CD70 was used for immunohistochemistry, because we have previously demonstrated that CD70 is a potential biomarker for ccRCC. 30, 55 The importance of immunohistochemical stainings in the correct identification of true ccpRCC was also highlighted by Williamson et al. 56 They studied 14 ccpRCC-like tumors, which could not be distinguished from ccpRCC morphologically, but which showed a high 3p deletion frequency (82%) and showed a different immunohistochemical profile, with negative or localized CK7 staining as the most striking feature. These characteristics also led to a reclassification of 1 of our tumors, primarily diagnosed as ccpRCC.
Recently, Schwartz et al studied different stem cell markers in renal cancers. They reported a 90% positivity rate for OCT3/4 in a series of 10 ccpRCC samples. 28 This reported a CD133 positivity rate of only 14% in ccRCC. It can therefore be concluded that CD133 is an additional tool to distinguish ccRCC from ccpRCC/RAT.
In concordance with Munari et al, 57 we found that about one third of ccpRCC are positive for GATA3, a protein crucial for the regulation of Th2 development and RAT cases. 12, 14, 59 This is comparable to multilocular cystic RCC, which has an excellent prognosis with no disease recurrence after surgery. 7, 12, 59 Specific molecular alterations may account for the indolent course of multilocular cystic RCC. Proposals have been put forward to rename multilocular cystic RCC as multilocular cystic renal cell neoplasm of low malignant potential to underscore this specific biological behavior. 1 Our group has reported that the expression of p27, CA-IX, CK7, and CK19 is associated with a better prognosis in sporadic RCC. 47, 60 Interestingly, our ccpRCC/RAT cases stained strongly positive for all of these markers. Hence, the indolent clinical course of ccpRCC/RAT might in part be due to this specific signaling pathway. However, some of the low-grade ccRCCs included in our previous publications may in fact be unrecognized ccpRCC. 35, 47 In summary, we have demonstrated that ccpRCC and RAT cannot be distinguished from one another by immunohistochemistry and molecular analyses, and both follow a benign clinical course. We regard them as a spectrum of a distinct tumor entity. Precise diagnosis is crucial, as it has an excellent prognosis. Given the reliability of TFE3 immunohistochemistry, TFE3 FISH should be performed in cases with equivocal TFE3 immunohistochemistry. 37 Taking into account the controversial relevance of the VHL mutation analysis in this differential diagnosis, direct VHL sequencing is not helpful in separation of ccRCC with prominent smooth muscle stroma from RAT. Our results suggest that a panel of antibodies against CK7, parafibromin, and MET is a helpful tool to differentiate most ccpRCCs/RATs from other renal tumors (Table 5 ). In some difficult cases VHL mutation testing and TFE3 FISH analysis are helpful tools to distinguish ccRCC and TFE3 translocation carcinoma from ccpRCC/RAT. 
